DOCSLIB.ORG

The Delayed Effects of Respiratory Syncytial Virus Infection

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Delayed Effects of Respiratory Syncytial Virus Infection THE DELAYED EFFECTS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION Thesis submitted for the degree of Doctor of Philosophy in the faculty of Clinical Sciences of the University of London by Diarmuid Rodney O’Donnell Respiratory Medicine St. Mary's Hospital Medical School at Imperial College Norfolk Place London August 1996 Abstract Respiratory Syncytial (RS) virus is the most important respiratory pathogen of infants. The role of RS virus, in the pathogenesis of wheezing and asthma has been a topic of medical interest for many years. Many questions about the pathogenesis of RS virus disease remain unanswered. With new techniques, answers to some of these questions can be attempted. In this thesis, novel techniques were used in studies of RS virus infected infants, children and adults, and mice. Using a nested reverse transcriptase polymerase chain reaction (RT-PCR), it was shown that cell associated viraemia occurs in some infants hospitalised with bronchiolitis but that RS virus cannot be detected in serum or cerebrospinal fluid. RT-PCR was also used to determine, first, the frequency of RS virus in nasopharyngeal aspirates from children admitted with respiratory illnesses, and, in bronchoalveolar lavage fluid from adults infected with human immunodeficiency virus being investigated for unexplained respiratory symptoms. In mice, RT-PCR showed that RS virus persists for at least 100 days after acute infection. Almost all the isolates sequenced from these mice contained an unchanged dominant epitope for cytotoxic lymphocyte (CTL) recognition and all the mice tested had vigorous CTL recognising this epitope. A mutant epitope was also detected, but extensive studies using synthetic peptides did not show interference or inhibition of CTL responses by this mutant. The effect of RS and influenza A virus infections on the immune response to an inhaled protein antigen (ovalbumin) was studied. In the presence of viral infection, acute anaphylaxis and exaggerated TH2 responses to ovalbumin were shown, without the use of adjuvant. This comprises a novel finding of possible clinical significance. By showing viral persistence and altered responses to other antigens, these studies may in part explain the delayed effects of RS virus infection in man. 1 Acknowledgements In the last few years, there have been many people who have given me important practical and theoretical help and teaching. Many times during this work, the results confounded my initial expectations and I must particularly thank my supervisor Peter Openshaw for great patience, support and attention to detail. My thanks also go to all of my friends in the lab: Andy Georgiou for teaching and shared frustration with the flow cytometer, Tracy Hussell for her wide experience of techniques and endless enthusiasm, Lindsay Spender for her shared interest in PCR and help with Southern blotting, Serene Foster for testing viruses and other stocks for Mycoplasma spp., as well as Stephen Rapecki and Tim Sparer. Special thanks must go to Pietro Pala, who arrived in the lab at a sad and difficult time, and who bravely read a large part of this thesis and offered many valuable suggestions. Virus stocks were kindly prepared for me by Tracy Hussell and Andy Georgiou. I thank Mike McGarvey for teaching me about PCR. Antibodies for intracellular cytokine staining were a gift of Anne O'Garra at DNAX. Adrian Hill kindly gave me peptides and Steve Cobbold generously provided T cell depleting antibodies and suggested possible protocols. John Clarke gave me bronchoalveolar lavage samples from adults with HIV and Seb Johnston sent me samples of RNA extracted from nasopharyngeal aspirates. Charlotte Hetzel provided me with an IgE standard for chapter 7. Brian Seymour working, for Robert Coffman at DNAX suggested modifications for the anti-ovalbumin capture ELISA. I would very much like to thank Professor Brigitte Askonas who helped me very much in writing both my application for Wellcome funding and this thesis. My thanks also to Rodney Phillips for useful discussions about peptide inhibition studies. Thanks must go to the Wellcome Tmst for awarding me a Training Fellowship and the British Lung Foundation who supported my first two years. Most of all I thank my wife Jane, who has supported me through the many frustrations, dead ends and sometimes exciting moments that have made up the three and a half years of this PhD. n Table of Contents Abstract................................................................................................................................ i Acknowledgements.............................................................................................................. ii Table of Contents ............................................................................................................ iii List of Figures.....................................................................................................................vii List of Tables ................................................................................................................. viii Abbreviations:................................................................................................................... ix Chapter 1 Introduction..........................................................................................................................1 Features of Respiratory Syncytial Virus:................................................................4 History.......................................................................................................... 4 Epidemiology................................................................................................4 Taxonomy:....................................................................................................6 Molecular Biology.......................................................................................7 Proteins of RS virus.....................................................................................8 Infectious cycle ....................................................................................... 10 In vivo ......................................................................................... 10 In vitro......................................................................................... 11 Clinical features: ..................................................................................... 13 Pathophysiology....................................................................................... 15 The Immune response to RS virus...................................................................... 16 Humoral Immunity................................................................................... 17 Cellular Mediated Immunity .................................................................. 18 Antigen recognition by T cells................................................................ 19 MHC and peptide binding ...................................................................... 19 Avidity versus conformational change................................................... 21 Co-stimulatory molecules...........................................................................22 Mechanisms of viral clearance ..................................................................22 Formalin inactivated vaccine.....................................................................25 T cell subsets: T helper 1 and T helper 2 after vaccination ......................25 The delayed effects of respiratory syncytial virus infection ....................28 Chapter 2 Materials and m ethods.....................................................................................................33 Solutions and Chemicals Used...............................................................................33 Respiratory Syncytial Virus ................................................................................... 33 Microplaque assay for infective virus ..................................................................34 Vaccinia Recombinants..........................................................................................34 Mouse Experiments................................................................................................35 iii Intranasal infection ................................................................................................35 Injection of depleting antibodies i.v........................................................................35 Recovery of tissues from mice...............................................................................36 Exposure to ovalbumin by nebulisation................................................................36 Immunological Methods ....................................................................................... 37 Spleen cell bulk culture .............................................................................37 Preparing Targets ....................................................................................... 38 Bioassay for cytokines IL-2 and IL-4........................................................39 ELISA........................................................................................................ 39 IgE, IgGl or IgG2a to ovalbumin in mouse serum ......................39 total IgE in mouse serum ..............................................................40 Anti-RSV ELISA...........................................................................40 Flow Cytometry..........................................................................................41
Load more

Recommended publications
  • The Story of César Milstein and Monoclonal Antibodies: Introduction Page 1 of 4
    The Story of César Milstein and Monoclonal Antibodies: Introduction Page 1 of 4 Custom Search Search A HEALTHCARE REVOLUTION IN THE MAKING The Story of César Milstein and Monoclonal Antibodies Collated and written by Dr Lara Marks Today six out of ten of the best selling drugs in the world are monoclonal antibody therapeutics. One of these, Humira®, which is a treatment for rheumatoid arthritis and other autoimmune conditions, was listed as the top selling drug across the globe in 2012 with a revenue of US$9.3 billion. Based on its current performance many predict the annual sales of the drug will surpass the peak sales of Lipitor, a treatment for lowering cholesterol, that is the best selling therapeutic of all time. Currently monoclonal antibody drugs make up a third of all new medicines introduced worldwide. http://www.whatisbiotechnology.org/exhibitions/milstein 4/13/2017 PFIZER EX. 1524 Page 1 The Story of César Milstein and Monoclonal Antibodies: Introduction Page 2 of 4 Portrait of César Milstein. Photo credit: Godfrey Argent Studio Monoclonal antibodies are not only successful drugs, but are powerful tools for a wide range of medical applications. On the research front they are essential probes for determining the pathological pathway and cause of diseases like cancer and autoimmune and neurological disorders. They are also used for typing blood and tissue, a process that is vital to blood transfusion and organ transplants. In addition, monoclonal antibodies are critical components in diagnostics, having increased the speed and accuracy of tests. Today the antibodies are used for the detection of multiple conditions, ranging from pregnancy and heart attacks, to pandemic flu, AIDS and diseases like anthrax and smallpox released by biological weapons.
    [Show full text]
  • Smutty Alchemy
    University of Calgary PRISM: University of Calgary's Digital Repository Graduate Studies The Vault: Electronic Theses and Dissertations 2021-01-18 Smutty Alchemy Smith, Mallory E. Land Smith, M. E. L. (2021). Smutty Alchemy (Unpublished doctoral thesis). University of Calgary, Calgary, AB. http://hdl.handle.net/1880/113019 doctoral thesis University of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission. Downloaded from PRISM: https://prism.ucalgary.ca UNIVERSITY OF CALGARY Smutty Alchemy by Mallory E. Land Smith A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY GRADUATE PROGRAM IN ENGLISH CALGARY, ALBERTA JANUARY, 2021 © Mallory E. Land Smith 2021 MELS ii Abstract Sina Queyras, in the essay “Lyric Conceptualism: A Manifesto in Progress,” describes the Lyric Conceptualist as a poet capable of recognizing the effects of disparate movements and employing a variety of lyric, conceptual, and language poetry techniques to continue to innovate in poetry without dismissing the work of other schools of poetic thought. Queyras sees the lyric conceptualist as an artistic curator who collects, modifies, selects, synthesizes, and adapts, to create verse that is both conceptual and accessible, using relevant materials and techniques from the past and present. This dissertation responds to Queyras’s idea with a collection of original poems in the lyric conceptualist mode, supported by a critical exegesis of that work.
    [Show full text]
  • Eulogy Professor Emeritus Brigitte A. Askonas You Have Doubtless Often
    Eulogy Professor Emeritus Brigitte A. Askonas You have doubtless often heard it said that such a person needs no introduction. Well, I reckon the recipient of the 2007 Robert Koch Gold Medal deserves an introduction. I would like to introduce her, as she is not someone to blow her own trumpet. She would never describe herself as the grand dame of cellular immunology. She would never talk about the great influence she has had on immunology. She would never say that she has mentored countless outstanding scientists. She would never proudly list all her honorary memberships of scientific societies and academies and all her honorary professorships at top universities. Professor Brigitte Askonas is not very forthcoming about her successes, which is precisely why an introduction is necessary. We would like her to know how much we value her contributions to science and how impressed we are by the formative influence she has had on the biosciences in Europe and in particular on immunology. Ita Askonas started her scientific career as a biochemist. In 1944, she was awarded a bachelor’s degree in biochemistry from McGill University in Montreal, Canada. In 1952, she received her PhD from the Biochemistry Department of the University of Cambridge in the United Kingdom, where she served her scientific apprenticeship under Malcolm Dixon. She studied muscle enzymes, by no means the worst grounding for her subsequent research. After completing her doctorate, she became a member of the Scientific Staff at the National Institute of Medical Research in Mill Hill, London. There, she first continued with her enzyme studies and biochemical research.
    [Show full text]
  • Oralhisttransretro00maririch.Pdf
    University of California Berkeley of Regional Oral History Office University California The Bancroft Library Berkeley, California MARIAN E. KOSHLAND (1921-1997): RETROSPECTIVES ON A LIFE IN ACADEMIC SCIENCE, FAMILY, AND COMMUNITY ACTIVITIES James P. Allison Anne H. Good Catherine P. Koshland Daniel E. Koshland, Jr. Douglas E. Koshland James M. Koshland Hugh O. McDevitt Gail Koshland Wachtel Introduction by Daniel E. Koshland, Jr. Interviews Conducted by Sally Smith Hughes in 1999 and 2000 Copyright 2003 by The Regents of the University of California Since 1954 the Regional Oral History Office has been interviewing leading participants in or well-placed witnesses to major events in the development of northern California, the West, and the nation. Oral history is a method of collecting historical information through tape-recorded interviews between a narrator with firsthand knowledge of historically significant events and a well-informed interviewer, with the goal of preserving substantive additions to the historical record. The tape recording is transcribed, lightly edited for continuity and clarity, and reviewed by the interviewee. The corrected manuscript is indexed, bound with photographs and illustrative materials, and placed in The Bancroft Library at the University of California, Berkeley, and in other research collections for scholarly use. Because it is primary material, oral history is not intended to present the final, verified, or complete narrative of events. It is a spoken account, offered by the interviewee in response to questioning, and as such it is reflective, partisan, deeply involved, and irreplaceable. * * * * * if * * * * * * * * ** ** * * * ** * ** * * * * ** * * * * All uses of this manuscript are covered by a legal agreement between The Regents of the University of California and Daniel Koshland, December 14, 1998; Hugh McDevitt dated November 23, 1999; James M.
    [Show full text]
  • General Kofi A. Annan the United Nations United Nations Plaza
    MASSACHUSETTS INSTITUTE OF TECHNOLOGY DEPARTMENT OF PHYSICS CAMBRIDGE, MASSACHUSETTS O2 1 39 October 10, 1997 HENRY W. KENDALL ROOM 2.4-51 4 (617) 253-7584 JULIUS A. STRATTON PROFESSOR OF PHYSICS Secretary- General Kofi A. Annan The United Nations United Nations Plaza . ..\ U New York City NY Dear Mr. Secretary-General: I have received your letter of October 1 , which you sent to me and my fellow Nobel laureates, inquiring whetHeTrwould, from time to time, provide advice and ideas so as to aid your organization in becoming more effective and responsive in its global tasks. I am grateful to be asked to support you and the United Nations for the contributions you can make to resolving the problems that now face the world are great ones. I would be pleased to help in whatever ways that I can. ~~ I have been involved in many of the issues that you deal with for many years, both as Chairman of the Union of Concerne., Scientists and, more recently, as an advisor to the World Bank. On several occasions I have participated in or initiated activities that brought together numbers of Nobel laureates to lend their voices in support of important international changes. -* . I include several examples of such activities: copies of documents, stemming from the . r work, that set out our views. I initiated the World Bank and the Union of Concerned Scientists' examples but responded to President Clinton's Round Table initiative. Again, my appreciation for your request;' I look forward to opportunities to contribute usefully. Sincerely yours ; Henry; W.
    [Show full text]
  • Spotlight on Graduation Behind the Scenes at the Postgraduate Awards Ceremonies Centre Pages
    reporter www.imperial.ac.uk Issue 177 • 16 May 2007 Spotlight on Graduation Behind the scenes at the Postgraduate Awards Ceremonies centre pages Hot off the press Keeping in touch Hannah Gay’s Ambassadors visit official history of alumni around the globe Imperial launched PAGE 5 PAGE 3 in brief Caulcott to manage research Dr Celia Caulcott has joined the College as Research Manager on 3 May. Working to Celebrate in style the Deputy Rector, Professor Sir Leszek Borysiewicz, she will The Centenary Ball be responsible for the coordination of research Come celebrate 100 years of living activity between the science at the largest formal dinner faculties and for promoting the College’s central strategic research direction. Collaboration at the and party of the Centenary year. boundaries of faculties, departments and centres is With big name acts and DJs all night, plus an important area of growth and represents a major a fun fair, casino, big wheel, dodgems, opportunity for the College. Dr Caulcott’s role will be to facilitate the multi-dimensional and complex carousel, laser quest and giant table football! series of interactions that constitute modern Special VIP tickets are available: research and to ensure that external funders see Join over 2,000 staff, students, and alumni on to staff and alumni which grant access a ‘joined up’ approach by the various component to the VIP bar. The VIP bar will have Saturday 16 June 2007. Visit the website for complimentary champagne and parts of the College. full details and tickets. entertainment throughout the night and offers the perfect place to mingle McComb with friends.
    [Show full text]
  • 1990 to 2000 Lister Annual Report and Account
    The Lister Institute of Preventive Medicine Report of the Governing Body 1990 Brockley Hill Stanmore Middlesex HA7 4JD The Governing Body Professor G S Dawes, CBE, DM, FRCP, FRS, Chairman D C Hobson, MA, FCA, Hon Treasurer Professor H J Evans, PhD, FRSE C E Guinness, CVO The Rt Hon the Earl of Iveagh Dr Anne L McLaren, MA, DPhil, FRCOG, FRS Professor D K Peters, MB, BCh, FRCP Professor Sir Mark Richmond, PhD, ScD, FRCPath, FRS Dr A Robertson, CBE, PhD G T Sammons, MA Sir James Gowans, CBE, FRCP, FRS, resigned on 24 November 1989. Secretary, and Clerk to the Governors G J Roderick, BCom Solicitors: A uditors: Macfarlanes Coopers & Lybrand Deloitte 10 Norwich Street Plumtree Court London EC4A 1BD London EC4A 4HT Registered Charity No. 206271 Scientific Advisory Committee Dr Anne L McLaren, MA, DPhil, FRCOG, FRS, Chairman (appointed 1 January 1990) Dr M J C ru m p to n , PhD, FRS Professor H J Evans, PhD, FRSE Professor S Gordon, MB, ChB Professor P J Lachmann, ScD, FRCP, FRS Professor K Murray, PhD, FRS (appointed 12 June 1989) Professor Anne E Warner, PhD, FRS Sir James Gowans, CBE, FRCP, FRS, who was Chairman of the Scientific Advisory Committee as at 1 January 1989, resigned on 24 November 1989. Professor A D Smith, MA, DPhil, retired on 12 June 1989. 2 The Lister Institute of Preventive Medicine Annual General Meeting 5th June 1990 Report of the Governing Body Governing Body and Scientific Advisory Committee There has been one change in the composition of the Governing Body during the past year.
    [Show full text]
  • The Story of César Milstein and Monoclonal Antibodies: Introduction Page 1 of 3
    The Story of César Milstein and Monoclonal Antibodies: Introduction Page 1 of 3 A HEALTHCARE REVOLUTION IN THE MAKING The Story of César Milstein and Monoclonal Antibodies Collated and written by Dr Lara Marks Today six out of ten of the best selling drugs in the world are monoclonal antibody therapeutics. One of these, Humira®, which is a treatment for rheumatoid arthritis and other autoimmune conditions, was listed as the top selling drug across the globe in 2012 with a revenue of US$9.3 billion. Based on its current performance many predict the annual sales of the drug will surpass the peak sales of Lipitor, a treatment for lowering cholesterol, that is the best selling therapeutic of all time. Currently monoclonal antibody drugs make up a third of all new medicines introduced worldwide. 1 of 63 Celltrion, Inc., Exhibit 1024 http://www.whatisbiotechnology.org/exhibitions/milstein 9/8/2015 The Story of César Milstein and Monoclonal Antibodies: Introduction Page 2 of 3 Portrait of César Milstein. Photo credit: Godfrey Argent Studio Monoclonal antibodies are not only successful drugs, but are powerful tools for a wide range of medical applications. On the research front they are essential probes for determining the pathological pathway and cause of diseases like cancer and autoimmune and neurological disorders. They are also used for typing blood and tissue, a process that is vital to blood transfusion and organ transplants. In addition, monoclonal antibodies are critical components in diagnostics, having increased the speed and accuracy of tests. Today the antibodies are used for the detection of multiple conditions, ranging from pregnancy and heart attacks, to pandemic flu, AIDS and diseases like anthrax and smallpox released by biological weapons.
    [Show full text]
  • Brigitte Askonas 1923–2013
    ObiTuarY Brigitte Askonas 1923–2013 Emil R Unanue Brigitte Askonas, known to her friends as ‘Ita’, passed away peacefully pass that unique trait on to her trainees. I had a great experience with on 9 January 2013 after a brief illness with cancer, a few months short her, and my time spent under her mentorship changed my career. She of her 90th birthday. Ita lived a long, full and enjoyable life and made was incredibly unselfish, and when I formed my own laboratory after major contributions to the understanding of the immune system. She leaving Mill Hill, she allowed me to continue the work that she and made countless friends in and out of science and was highly influ- I had started. We kept in touch over the years, and she continued to ential in molding the careers of many. She was universally loved and follow my work. Ita was always there to provide me with her objective respected and, in return, she genuinely cared deeply for her many opinions, criticisms and suggestions on the work. She would let me friends. Her curiosity and enthusiasm for biology, and her keen and know when she disagreed with me. I came to value these interactions critical eye for scientific excellence, never dwindled one bit over her greatly and I respected the time and effort she spent helping not only long and illustrious career. me but also others. The reason I have emphasized my experiences Ita thoroughly relished her entire career that spanned her entrance in her laboratory and afterward and her influence on my future is to into the field of immunology in the mid-1950s (when the cellular make the point that such experiences were not restricted to me.
    [Show full text]
  • Increased in Ankylosing Spondylitis Responsive to HLA-B27
    Th17 Cells Expressing KIR3DL2+ and Responsive to HLA-B27 Homodimers Are Increased in Ankylosing Spondylitis This information is current as Paul Bowness, Anna Ridley, Jacqueline Shaw, Antoni T. of September 26, 2021. Chan, Isabel Wong-Baeza, Myles Fleming, Fraser Cummings, Andrew McMichael and Simon Kollnberger J Immunol 2011; 186:2672-2680; Prepublished online 19 January 2011; doi: 10.4049/jimmunol.1002653 Downloaded from http://www.jimmunol.org/content/186/4/2672 Supplementary http://www.jimmunol.org/content/suppl/2011/01/19/jimmunol.100265 Material 3.DC1 http://www.jimmunol.org/ References This article cites 33 articles, 9 of which you can access for free at: http://www.jimmunol.org/content/186/4/2672.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 26, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Th17 Cells Expressing KIR3DL2+ and Responsive to HLA-B27 Homodimers Are Increased in Ankylosing Spondylitis Paul Bowness,*,† Anna Ridley,* Jacqueline Shaw,* Antoni T.
    [Show full text]
  • César Milstein, CH, FRS (1927-2002)
    C. Milstein NCUACS 146/3/06 Catalogue of the papers and correspondence of César Milstein, CH, FRS (1927-2002) By Heather Bird and Timothy E. Powell C. Milstein NCUACS catalogue no.146/3/06 Title: Catalogue of the papers and correspondence of César Milstein CH FRS (1927-2002), molecular biologist Compiled by: Heather Bird and Timothy E. Powell Date of material: 1952-2003 Extent of material: ca 1,050 items Deposited in: Churchill Archives Centre, Churchill College, Cambridge Reference code: GB 0014 MSTN 2006 National Cataloguing Unit for the Archives of Contemporary Scientists, University of Bath C. Milstein NCUACS catalogue no. 146/3/06 NOT ALL THE MATERIAL IN THIS COLLECTION MAY YET BE AVAILABLE FOR CONSULTATION. ENQUIRIES SHOULD BE ADDRESSED IN THE FIRST INSTANCE TO: THE DIRECTOR CHURCHILL ARCHIVES CENTRE CHURCHILL COLLEGE CAMBRIDGE C. Milstein The work of the National Cataloguing Unit for the Archives of Contemporary Scientists in the production of this catalogue was made possible by the support of the Wellcome Trust Research Resources in Medical History programme C. Milstein LIST OF CONTENTS Items Page GENERAL INTRODUCTION 5 SECTION A BIOGRAPHICAL A.1-A.126 10 SECTION B LABORATORY OF MOLECULAR BIOLOGY B.1-B.84 32 SECTION C RESEARCH C.1-C.340 43 SECTION D LECTURES AND PUBLICATIONS D.1-D.152 94 SECTION E SOCIETIES AND ORGANISATIONS E.1-E.45 122 SECTION F CONSULTANCIES AND COMMERCIAL F.1-F.23 130 SECTION G VISITS AND CONFERENCES G.1-G.94 135 SECTION H CORRESPONDENCE H.1-H.187 156 INDEX OF CORRESPONDENTS 183 C.
    [Show full text]
  • Regional Oral History Office the Bancroft Library University Of
    Regional Oral History Office University of California The Bancroft Library Berkeley, California MARIAN E. KOSHLAND (1 92 1-1 997): RETROSPECTIVES ON A LIFE IN ACADEMIC SCIENCE, FAMlLY, AND COMMUNITY ACTMTIES James P. Allison Anne H. Good Catherine P. Koshland Daniel E. Koshland, Jr. Douglas E. Koshland James M. Koshland Hugh 0.McDevitt Gail Koshland Wachtel Introduction by Daniel E. Koshland, Jr. Interviews Conducted by Sally Smith Hughes in 1999 and 2000 Copyright O 2003 by The Regents of the University of California Since 1954 the Regional Oral History Office has been interviewing leading participants in or well-placed witnesses to major events in the development of northern California, the West, and the nation. Oral history is a method of collecting historical information through tape-recorded interviews between a narrator with firsthand knowledge of historically significant events and a well-informed interviewer, with the goal of preserving substantive additions to the historical record. The tape recording is transcribed, lightly edited for continuity and clarity, and reviewed by the interviewee. The corrected manuscript is indexed, bound with photographs and illustrative materials, and placed in The Bancroft Library at the University of California, Berkeley, and in other research collections for scholarly use. Because it is primary material, oral history is not intended to present the final, verified, or complete amative of events. It is a spoken account, offered by the interviewee in response to questioning, and as such it is reflective, partisan, deeply involved, and irreplaceable. All uses of this manuscript are covered by a legal agreement between The Regents of the University of California and Daniel Koshland, December 14, 1998; Hugh McDevitt dated November 23, 1999; James M.
    [Show full text]